Cytokinetics - Biotech company sees share jump after positive study results for Aficamten!
Reading Time: 1 minute
Business driver: Cytokinetics (CYTK) specializes in developing new methods for the treatment of muscular diseases, with Aficamten and Reldesemtiv being several promising compounds in advanced stages of clinical testing. On September 2, Cytokinetics presented promising Phase III clinical trial data for the drug Aficamten for the treatment of patients suffering from obstructive hypertrophic cardiomyopathy (oHCM), a rare muscle-related heart disease. On September 3, Barclays raised its price target from $53 to $71 and maintained its rating...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
